FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568475650> ?p ?o ?g. }

• W2568475650 endingPage "S1266" @default.
• W2568475650 startingPage "S1265" @default.
• W2568475650 abstract "Currently-available EGFR TKIs are ineffective for the treatment of brain metastases (BrM) due to limited blood-brain barrier (BBB) penetration. YH25448 is a potent, highly mutant-selective and irreversible 3rd generation EGFR TKI that is able to penetrate the BBB, and targets both the T790M mutation and activating EGFR mutations while sparing wild type (wt). The biochemical and pharmacological activity of YH25448 were characterized through in vitro kinase assays, and functional cell assays. The animal model with brain metastases from NSCLC was established by implanting luciferase-transfected NCI-H1975 human NSCLC cells carrying the L858R/T790M mutation both subcutaneously and intracranially into nude mice. In this animal model, YH25448 was compared with osimertinib in terms of tumor growth inhibition, survival, weight loss and clinical signs. The correlation of PK profiles (plasma, CSF and tumor tissues) with biological activity using inhibition of EGFR phosphorylation (pEGFR) in the tumor tissue was evaluated. YH25448 selectively inhibited EGFR single and double mutant kinase activity with IC50 values of 2 nM for L858R/T790M against 76 nM for wt-EGFR. In the cell proliferation assays, GI50 values were 6 nM, 5 nM, and 711 nM for H1975 cells (L858R/T790M), PC9 cells (del19) and H2073 cells (wt), respectively. In primary cancer cells from patients harboring EGFR mutations, YH25448 showed more potent inhibition of cancer cell growth compared to osimertinib. YH25448 treatment at the once-daily doses of 1-25 mg/kg resulted in dose-dependent tumor regression in both subcutaneous and intracranial lesions in mice implanted with H1975 cells. Given its high selectivity against wild type and wide safety margin, there were no changes in body weight and no abnormal clinical signs. At 10-25 mg/kg, YH25448 achieved more significant, complete tumor growth inhibition and longer overall survival compared to same doses of osimertinib. Dose-dependent inhibition of pEGFR expression in tumor tissue by YH25448 treatment was well translated into the in vivo efficacy. Plasma half-life of YH25448 was 5.9-6.8 hr and tumor to plasma AUC0-last ratio was 3.0-5.1. YH25448 also showed excellent penetration of the BBB, achieving CSF concentrations exceeding the IC50 value for pEGFR inhibition. The strong in vitro potency and high selectivity of YH25448 for mutant EGFR translated into robust in vivo efficacy. These findings indicate that YH25448 will be able to address the urgent unmet needs for EGFR mutant-positive patients with brain metastases." @default.
• W2568475650 created "2017-01-13" @default.
• W2568475650 creator A5006273113 @default.
• W2568475650 creator A5011980528 @default.
• W2568475650 creator A5028243041 @default.
• W2568475650 creator A5030572687 @default.
• W2568475650 creator A5043228545 @default.
• W2568475650 creator A5063229279 @default.
• W2568475650 creator A5064697305 @default.
• W2568475650 creator A5074733163 @default.
• W2568475650 creator A5075782991 @default.
• W2568475650 creator A5078821004 @default.
• W2568475650 creator A5081357584 @default.
• W2568475650 creator A5083673552 @default.
• W2568475650 creator A5088771895 @default.
• W2568475650 date "2017-01-01" @default.
• W2568475650 modified "2023-10-16" @default.
• W2568475650 title "P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC" @default.
• W2568475650 doi "https://doi.org/10.1016/j.jtho.2016.11.1787" @default.
• W2568475650 hasPublicationYear "2017" @default.
• W2568475650 type Work @default.
• W2568475650 sameAs 2568475650 @default.
• W2568475650 citedByCount "8" @default.
• W2568475650 countsByYear W25684756502018 @default.
• W2568475650 countsByYear W25684756502019 @default.
• W2568475650 countsByYear W25684756502020 @default.
• W2568475650 countsByYear W25684756502021 @default.
• W2568475650 countsByYear W25684756502022 @default.
• W2568475650 crossrefType "journal-article" @default.
• W2568475650 hasAuthorship W2568475650A5006273113 @default.
• W2568475650 hasAuthorship W2568475650A5011980528 @default.
• W2568475650 hasAuthorship W2568475650A5028243041 @default.
• W2568475650 hasAuthorship W2568475650A5030572687 @default.
• W2568475650 hasAuthorship W2568475650A5043228545 @default.
• W2568475650 hasAuthorship W2568475650A5063229279 @default.
• W2568475650 hasAuthorship W2568475650A5064697305 @default.
• W2568475650 hasAuthorship W2568475650A5074733163 @default.
• W2568475650 hasAuthorship W2568475650A5075782991 @default.
• W2568475650 hasAuthorship W2568475650A5078821004 @default.
• W2568475650 hasAuthorship W2568475650A5081357584 @default.
• W2568475650 hasAuthorship W2568475650A5083673552 @default.
• W2568475650 hasAuthorship W2568475650A5088771895 @default.
• W2568475650 hasBestOaLocation W25684756501 @default.
• W2568475650 hasConcept C104317684 @default.
• W2568475650 hasConcept C121608353 @default.
• W2568475650 hasConcept C126322002 @default.
• W2568475650 hasConcept C142724271 @default.
• W2568475650 hasConcept C143065580 @default.
• W2568475650 hasConcept C184235292 @default.
• W2568475650 hasConcept C202751555 @default.
• W2568475650 hasConcept C2776256026 @default.
• W2568475650 hasConcept C2777626846 @default.
• W2568475650 hasConcept C2777930144 @default.
• W2568475650 hasConcept C2778087573 @default.
• W2568475650 hasConcept C2779177807 @default.
• W2568475650 hasConcept C2779438470 @default.
• W2568475650 hasConcept C2780580887 @default.
• W2568475650 hasConcept C502942594 @default.
• W2568475650 hasConcept C54009773 @default.
• W2568475650 hasConcept C54355233 @default.
• W2568475650 hasConcept C55493867 @default.
• W2568475650 hasConcept C71924100 @default.
• W2568475650 hasConcept C81729549 @default.
• W2568475650 hasConcept C81885089 @default.
• W2568475650 hasConcept C86803240 @default.
• W2568475650 hasConcept C95444343 @default.
• W2568475650 hasConcept C98274493 @default.
• W2568475650 hasConceptScore W2568475650C104317684 @default.
• W2568475650 hasConceptScore W2568475650C121608353 @default.
• W2568475650 hasConceptScore W2568475650C126322002 @default.
• W2568475650 hasConceptScore W2568475650C142724271 @default.
• W2568475650 hasConceptScore W2568475650C143065580 @default.
• W2568475650 hasConceptScore W2568475650C184235292 @default.
• W2568475650 hasConceptScore W2568475650C202751555 @default.
• W2568475650 hasConceptScore W2568475650C2776256026 @default.
• W2568475650 hasConceptScore W2568475650C2777626846 @default.
• W2568475650 hasConceptScore W2568475650C2777930144 @default.
• W2568475650 hasConceptScore W2568475650C2778087573 @default.
• W2568475650 hasConceptScore W2568475650C2779177807 @default.
• W2568475650 hasConceptScore W2568475650C2779438470 @default.
• W2568475650 hasConceptScore W2568475650C2780580887 @default.
• W2568475650 hasConceptScore W2568475650C502942594 @default.
• W2568475650 hasConceptScore W2568475650C54009773 @default.
• W2568475650 hasConceptScore W2568475650C54355233 @default.
• W2568475650 hasConceptScore W2568475650C55493867 @default.
• W2568475650 hasConceptScore W2568475650C71924100 @default.
• W2568475650 hasConceptScore W2568475650C81729549 @default.
• W2568475650 hasConceptScore W2568475650C81885089 @default.
• W2568475650 hasConceptScore W2568475650C86803240 @default.
• W2568475650 hasConceptScore W2568475650C95444343 @default.
• W2568475650 hasConceptScore W2568475650C98274493 @default.
• W2568475650 hasIssue "1" @default.
• W2568475650 hasLocation W25684756501 @default.
• W2568475650 hasOpenAccess W2568475650 @default.
• W2568475650 hasPrimaryLocation W25684756501 @default.
• W2568475650 hasRelatedWork W2560717039 @default.
• W2568475650 hasRelatedWork W2597070303 @default.
• W2568475650 hasRelatedWork W2921871143 @default.

• next